Association of cardiac and non-cardiac chronic disease comorbidity on glycaemic control in a multi-ethnic population with type 1 and type 2 diabetes
- R L Mehta1,
- M J Davies2,
- S Ali3,
- N A Taub1,
- M A Stone1,
- R Baker1,
- P G McNally4,
- I G Lawrence4,
- K Khunti1
- 1Department of Health Sciences, University of Leicester, Leicester, UK
- 2Department of Cardiovascular Sciences, Leicester Royal Infirmary, Infirmary Close, University of Leicester, Leicester, UK
- 3Primary Care and Population Sciences, University of Southampton, Southampton, UK
- 4Department of Diabetes and Endocrinology, University Hospitals Leicester, Leicester Royal Infirmary, Infirmary Close, Leicester, UK
- Correspondence to R L Mehta, Department of Health Sciences, University of Leicester, 22–28 Princess Road West, Leicester LE1 6TP, UK;
- Received 1 July 2011
- Accepted 13 July 2011
- Published Online First 26 August 2011
Aims To determine the prevalence of chronic disease comorbidity in south Asians (SAs) and white Europeans (WEs) with diabetes and to quantify the relationship of cardiac disease comorbidity (CDCM) and non-cardiac disease comorbidity (NCCM) to glycaemic control in SAs and WEs with type 1 and type 2 diabetes mellitus.
Methods A cross-sectional study using a database of patients of SA (25.5%) and WE (74.5%) origin attending a specialist diabetes clinic in the UK between 2003 and 2005 (n=5664).
Results The prevalence of SAs and WEs with type 1 diabetes was 12% and 88%, respectively; for those with type 2 diabetes the prevalence was 30% and 70%, respectively. Overall, the prevalence of comorbidity in people with type 1 diabetes was 25.5% and with type 2 diabetes was 47%. NCCM was more prevalent in WEs than SAs (17.6% vs 12.8%, p<0.001). In type 2 diabetes, the prevalence of suboptimal glycaemic control was significantly greater in SAs compared to WEs with NCCM and CDCM (79% vs 62%, p<0.001; 78% vs 65%, p<0.001, respectively). SAs with type 2 diabetes and comorbidity had excess odds of suboptimal glycaemic control compared to WEs: OR 2.27 (95% CI 1.50 to 3.43) for those with NCCM and OR 1.91 (95% CI 1.49 to 2.44) for those with CDCM.
Conclusions The prevalence of CDCM is higher in SAs compared to WEs with type 2 diabetes, whereas the prevalence of NCCM is higher in WEs compared to SAs. Taking into account comorbidities, SAs (compared to WEs) with type 2 diabetes had an excess risk of having HbA1c ≥7% ranging from 1.86- to 2.27-fold. Further research is needed to identify the reasons for unfavourable metabolic conditions in SAs and also develop and evaluate interventions.
- glycaemic control
- diabetes mellitus
- chronic disease
- cardiac epidemiology
- coronary heart disease
- diabetes & endocrinology
- internal medicine
Competing interests None.
Ethics approval Leicestershire, Northamptonshire and Rutland Research Ethics Committee, UK.
Provenance and peer review Not commissioned; externally peer reviewed.